KRAS and non-small cell lung carcinoma: Moreover, one study (NCT01951690) [61] on NSCLC patients harboring KRAS mutation was discontinued due the death of 76% of patients, in addition another study failed phase II multicenter clinical trial (NCT01870609) targeting malignant pleural mesothelioma stem cells [62].